Header Logo

Connection

Christopher Goetz to Parkinson Disease

Back to Details
This is a "connection" page, showing publications Christopher Goetz has written about Parkinson Disease.
Christopher Goetz
Connection Strength
29.005
Parkinson Disease
  1. Reply to: Comment on "Summing MDS-UPDRS Parts 1?+?2 (Non-motor and Motor Experience of Daily Living): The Patient's Voice". Mov Disord. 2023 08; 38(8):1564.
    View in: PubMed
    Score: 0.486
  2. It Is as It Was: MDS-UPDRS Part III Scores Cannot Be Combined with Other Parts to Give a Valid Sum. Mov Disord. 2023 02; 38(2):342-347.
    View in: PubMed
    Score: 0.464
  3. The plight of loneliness in Parkinson's disease: New opportunities. Parkinsonism Relat Disord. 2022 Dec; 105:145-148.
    View in: PubMed
    Score: 0.461
  4. Reply to: Cognitive Effects of Deep Brain Stimulation in GBA-Related Parkinson's Disease. Ann Neurol. 2022 08; 92(2):345-346.
    View in: PubMed
    Score: 0.451
  5. Parkinson Disease and Subthalamic Nucleus Deep Brain Stimulation: Cognitive Effects in GBA Mutation Carriers. Ann Neurol. 2022 03; 91(3):424-435.
    View in: PubMed
    Score: 0.437
  6. Apathy in Parkinson disease: Why we should care. Neurology. 2020 11 17; 95(20):893-894.
    View in: PubMed
    Score: 0.399
  7. The Evolution-Driven Signature of Parkinson's Disease. Trends Neurosci. 2020 07; 43(7):475-492.
    View in: PubMed
    Score: 0.390
  8. Parkinson's disease: Is it a consequence of human brain evolution? Mov Disord. 2019 04; 34(4):453-459.
    View in: PubMed
    Score: 0.357
  9. What influences placebo and nocebo responses in Parkinson's disease? Mov Disord. 2018 08; 33(8):1204-1212.
    View in: PubMed
    Score: 0.345
  10. Closing the celebration of 200 years of Parkinson's Essay on the Shaking Palsy: Where do we go in the next 200 years? Mov Disord. 2017 12; 32(12):1651-1652.
    View in: PubMed
    Score: 0.327
  11. Gender-, age-, and race/ethnicity-based differential item functioning analysis of the movement disorder society-sponsored revision of the Unified Parkinson's disease rating scale. Mov Disord. 2016 12; 31(12):1865-1873.
    View in: PubMed
    Score: 0.305
  12. Failing as doorman and disc jockey at the same time: Amygdalar dysfunction in Parkinson's disease. Mov Disord. 2016 Jan; 31(1):11-22.
    View in: PubMed
    Score: 0.286
  13. Preface. Mov Disord. 2015 Sep 15; 30(11):1441.
    View in: PubMed
    Score: 0.280
  14. Handling missing values in the MDS-UPDRS. Mov Disord. 2015 Oct; 30(12):1632-8.
    View in: PubMed
    Score: 0.270
  15. Initial management of Parkinson's disease. BMJ. 2014 Dec 19; 349:g6258.
    View in: PubMed
    Score: 0.267
  16. Relationships among cognitive impairment, sleep, and fatigue in Parkinson's disease using the MDS-UPDRS. Parkinsonism Relat Disord. 2014 Nov; 20(11):1135-9.
    View in: PubMed
    Score: 0.261
  17. Comparison of the Movement Disorder Society Parkinson's disease dementia criteria with neuropsychological testing. Mov Disord. 2014 Sep; 29(10):1252-7.
    View in: PubMed
    Score: 0.256
  18. Are patients with Parkinson's disease blind to blindsight? Brain. 2014 Jun; 137(Pt 6):1838-49.
    View in: PubMed
    Score: 0.255
  19. Visuoperceptive region atrophy independent of cognitive status in patients with Parkinson's disease with hallucinations. Brain. 2014 Mar; 137(Pt 3):849-59.
    View in: PubMed
    Score: 0.251
  20. Relationship between the MDS-UPDRS domains and the health-related quality of life of Parkinson's disease patients. Eur J Neurol. 2014 Mar; 21(3):519-24.
    View in: PubMed
    Score: 0.251
  21. I finally see what you see: Parkinson's disease visual hallucinations captured with functional neuroimaging. Mov Disord. 2014 Jan; 29(1):115-7.
    View in: PubMed
    Score: 0.242
  22. Assessing the non-motor symptoms of Parkinson's disease: MDS-UPDRS and NMS Scale. Eur J Neurol. 2015 Jan; 22(1):37-43.
    View in: PubMed
    Score: 0.238
  23. The Parkinson's disease multidisciplinary package. Mov Disord. 2013 May; 28(5):565.
    View in: PubMed
    Score: 0.236
  24. Calibration of unified Parkinson's disease rating scale scores to Movement Disorder Society-unified Parkinson's disease rating scale scores. Mov Disord. 2012 Sep 01; 27(10):1239-42.
    View in: PubMed
    Score: 0.227
  25. Expanded and independent validation of the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS). J Neurol. 2013 Jan; 260(1):228-36.
    View in: PubMed
    Score: 0.227
  26. Clinical differences among mild cognitive impairment subtypes in Parkinson's disease. Mov Disord. 2012 Aug; 27(9):1129-36.
    View in: PubMed
    Score: 0.226
  27. Tai chi for patients with Parkinson's disease. N Engl J Med. 2012 05 03; 366(18):1737-8; author reply 1738.
    View in: PubMed
    Score: 0.223
  28. Vibration therapy for Parkinson's disease: Charcot's studies revisited. J Parkinsons Dis. 2012; 2(1):23-7.
    View in: PubMed
    Score: 0.218
  29. Clinical validation of Movement Disorder Society-recommended diagnostic criteria for Parkinson's disease with dementia. Mov Disord. 2012 Feb; 27(2):248-53.
    View in: PubMed
    Score: 0.217
  30. Temporal stability of the Unified Dyskinesia Rating Scale. Mov Disord. 2011 Dec; 26(14):2556-9.
    View in: PubMed
    Score: 0.213
  31. The history of Parkinson's disease: early clinical descriptions and neurological therapies. Cold Spring Harb Perspect Med. 2011 Sep; 1(1):a008862.
    View in: PubMed
    Score: 0.213
  32. Wearing-off scales in Parkinson's disease: critique and recommendations. Mov Disord. 2011 Oct; 26(12):2169-75.
    View in: PubMed
    Score: 0.211
  33. Visual plus nonvisual hallucinations in Parkinson's disease: development and evolution over 10 years. Mov Disord. 2011 Oct; 26(12):2196-200.
    View in: PubMed
    Score: 0.211
  34. An update expert opinion on management and research strategies in Parkinson's disease psychosis. Expert Opin Pharmacother. 2011 Sep; 12(13):2009-24.
    View in: PubMed
    Score: 0.209
  35. Racial differences may influence the role of cholecystokinin polymorphisms in Parkinson's disease hallucinations. Mov Disord. 2011 Aug 01; 26(9):1781-2.
    View in: PubMed
    Score: 0.207
  36. Scales to assess sleep impairment in Parkinson's disease: critique and recommendations. Mov Disord. 2010 Dec 15; 25(16):2704-16.
    View in: PubMed
    Score: 0.202
  37. Hallucinations and sleep disorders in PD: ten-year prospective longitudinal study. Neurology. 2010 Nov 16; 75(20):1773-9.
    View in: PubMed
    Score: 0.200
  38. Cancer incidence in a trial of an antiapoptotic agent for Parkinson's disease. Mov Disord. 2010 Sep 15; 25(12):1801-8.
    View in: PubMed
    Score: 0.199
  39. Teaching program for the Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale: (MDS-UPDRS). Mov Disord. 2010 Jul 15; 25(9):1190-4.
    View in: PubMed
    Score: 0.197
  40. New developments in depression, anxiety, compulsiveness, and hallucinations in Parkinson's disease. Mov Disord. 2010; 25 Suppl 1:S104-9.
    View in: PubMed
    Score: 0.190
  41. [Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS): a new scale for the evaluation of Parkinson's disease]. Rev Neurol (Paris). 2010 Jan; 166(1):1-4.
    View in: PubMed
    Score: 0.188
  42. Jean-Martin Charcot and his vibratory chair for Parkinson disease. Neurology. 2009 Aug 11; 73(6):475-8.
    View in: PubMed
    Score: 0.184
  43. Hallucinations in Parkinson disease. Nat Rev Neurol. 2009 Jun; 5(6):331-42.
    View in: PubMed
    Score: 0.182
  44. Dysautonomia rating scales in Parkinson's disease: sialorrhea, dysphagia, and constipation--critique and recommendations by movement disorders task force on rating scales for Parkinson's disease. Mov Disord. 2009 Apr 15; 24(5):635-46.
    View in: PubMed
    Score: 0.180
  45. Parkinson's disease dementia: definitions, guidelines, and research perspectives in diagnosis. Ann Neurol. 2008 Dec; 64 Suppl 2:S81-92.
    View in: PubMed
    Score: 0.176
  46. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord. 2008 Nov 15; 23(15):2129-70.
    View in: PubMed
    Score: 0.175
  47. Apathy and anhedonia rating scales in Parkinson's disease: critique and recommendations. Mov Disord. 2008 Oct 30; 23(14):2004-14.
    View in: PubMed
    Score: 0.175
  48. Anxiety rating scales in Parkinson's disease: critique and recommendations. Mov Disord. 2008 Oct 30; 23(14):2015-25.
    View in: PubMed
    Score: 0.175
  49. The placebo treatments in neurosciences: New insights from clinical and neuroimaging studies. Neurology. 2008 Aug 26; 71(9):677-84.
    View in: PubMed
    Score: 0.173
  50. Antipsychotic medication treatment for mild hallucinations in Parkinson's disease: Positive impact on long-term worsening. Mov Disord. 2008 Aug 15; 23(11):1541-5.
    View in: PubMed
    Score: 0.172
  51. Evaluating Parkinson's disease patients at home: utility of self-videotaping for objective motor, dyskinesia, and ON-OFF assessments. Mov Disord. 2008 Jul 30; 23(10):1479-82.
    View in: PubMed
    Score: 0.172
  52. Visual hallucinations and symptoms of REM sleep behavior disorder in Parkinsonian tauopathies. Int J Geriatr Psychiatry. 2008 Jun; 23(6):598-603.
    View in: PubMed
    Score: 0.170
  53. Placebo influences on dyskinesia in Parkinson's disease. Mov Disord. 2008 Apr 15; 23(5):700-7.
    View in: PubMed
    Score: 0.168
  54. Placebo response in Parkinson's disease: comparisons among 11 trials covering medical and surgical interventions. Mov Disord. 2008 Apr 15; 23(5):690-9.
    View in: PubMed
    Score: 0.168
  55. Scales to assess psychosis in Parkinson's disease: Critique and recommendations. Mov Disord. 2008 Mar 15; 23(4):484-500.
    View in: PubMed
    Score: 0.167
  56. Diagnostic criteria for psychosis in Parkinson's disease: report of an NINDS, NIMH work group. Mov Disord. 2007 Jun 15; 22(8):1061-8.
    View in: PubMed
    Score: 0.159
  57. Depression rating scales in Parkinson's disease: critique and recommendations. Mov Disord. 2007 Jun 15; 22(8):1077-92.
    View in: PubMed
    Score: 0.159
  58. Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial. Mov Disord. 2007 Jan 15; 22(2):179-86.
    View in: PubMed
    Score: 0.154
  59. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan. Mov Disord. 2007 Jan; 22(1):41-7.
    View in: PubMed
    Score: 0.154
  60. Motor function in Parkinson's disease and supranuclear palsy: simultaneous factor analysis of a clinical scale in several populations. BMC Med Res Methodol. 2006 Jun 13; 6:26.
    View in: PubMed
    Score: 0.148
  61. Does seasonal variation affect hallucinations in PD? A longitudinal study. Mov Disord. 2006 Jun; 21(6):863-5.
    View in: PubMed
    Score: 0.148
  62. Safety of rasagiline in elderly patients with Parkinson disease. Neurology. 2006 May 09; 66(9):1427-9.
    View in: PubMed
    Score: 0.147
  63. The malignant course of "benign hallucinations" in Parkinson disease. Arch Neurol. 2006 May; 63(5):713-6.
    View in: PubMed
    Score: 0.147
  64. Age-related influences on the clinical characteristics of new-onset hallucinations in Parkinson's disease patients. Mov Disord. 2006 Feb; 21(2):267-70.
    View in: PubMed
    Score: 0.144
  65. What's new? Clinical progression and staging of Parkinson's disease. J Neural Transm Suppl. 2006; (70):305-8.
    View in: PubMed
    Score: 0.144
  66. Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004. Mov Disord. 2005 May; 20(5):523-39.
    View in: PubMed
    Score: 0.137
  67. Hallucinations and sleep disorders in PD: six-year prospective longitudinal study. Neurology. 2005 Jan 11; 64(1):81-6.
    View in: PubMed
    Score: 0.134
  68. Movement disorders: understanding clinical trials. Lancet Neurol. 2005 Jan; 4(1):5-6.
    View in: PubMed
    Score: 0.134
  69. Assuring interrater reliability for the UPDRS motor section: utility of the UPDRS teaching tape. Mov Disord. 2004 Dec; 19(12):1453-6.
    View in: PubMed
    Score: 0.133
  70. Short-term and practice effects of metronome pacing in Parkinson's disease patients with gait freezing while in the 'on' state: randomized single blind evaluation. Parkinsonism Relat Disord. 2004 Dec; 10(8):507-10.
    View in: PubMed
    Score: 0.133
  71. Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations. Mov Disord. 2004 Sep; 19(9):1020-8.
    View in: PubMed
    Score: 0.131
  72. Re: UPDRS: Status and recommendations. Mov Disord. 2004 May; 19(5):605.
    View in: PubMed
    Score: 0.128
  73. Standardized training tools for the UPDRS activities of daily living scale: newly available teaching program. Mov Disord. 2003 Dec; 18(12):1455-8.
    View in: PubMed
    Score: 0.124
  74. Wheeled and standard walkers in Parkinson's disease patients with gait freezing. Parkinsonism Relat Disord. 2003 Oct; 10(1):9-14.
    View in: PubMed
    Score: 0.123
  75. Impact of placebo assignment in clinical trials of Parkinson's disease. Mov Disord. 2003 Oct; 18(10):1146-9.
    View in: PubMed
    Score: 0.123
  76. Coping strategies for visual hallucinations in Parkinson's disease. Mov Disord. 2003 Jul; 18(7):831-2.
    View in: PubMed
    Score: 0.121
  77. Summing MDS-UPDRS Parts 1?+?2 (Non-motor and Motor Experience of Daily Living): The Patient's Voice. Mov Disord. 2023 07; 38(7):1363-1364.
    View in: PubMed
    Score: 0.119
  78. Parkinson disease with old-age onset: a comparative study with subjects with middle-age onset. Arch Neurol. 2003 Apr; 60(4):529-33.
    View in: PubMed
    Score: 0.119
  79. An open label, non-randomized study assessing a prebiotic fiber intervention in a small cohort of Parkinson's disease participants. Nat Commun. 2023 02 18; 14(1):926.
    View in: PubMed
    Score: 0.118
  80. Cross-Cultural Differences in Patient Perceptions of Dyskinesia in Parkinson's Disease. Mov Disord. 2023 04; 38(4):688-692.
    View in: PubMed
    Score: 0.117
  81. Using Movement Disorder Society Unified Parkinson's Disease Rating Scale Parts 2 and 3 Simultaneously: Combining the Patient Voice with Clinician Ratings. Mov Disord. 2023 03; 38(3):453-463.
    View in: PubMed
    Score: 0.117
  82. Intestinal microbiota and neuroinflammation in Parkinson's disease: At the helm of the gut-brain axis. Int Rev Neurobiol. 2022; 167:81-99.
    View in: PubMed
    Score: 0.114
  83. Progressive worsening of spatial and chromatic processing deficits in Parkinson disease. Arch Neurol. 2002 Aug; 59(8):1249-52.
    View in: PubMed
    Score: 0.113
  84. Dissecting the Domains of Parkinson's Disease: Insights from Longitudinal Item Response Theory Modeling. Mov Disord. 2022 09; 37(9):1904-1914.
    View in: PubMed
    Score: 0.113
  85. Resolving Missing Data from the Movement Disorder Society Unified Parkinson's Disease Rating Scale: Implications for Telemedicine. Mov Disord. 2022 08; 37(8):1749-1755.
    View in: PubMed
    Score: 0.112
  86. Gut microbial metabolites in Parkinson's disease: Association with lifestyle, disease characteristics, and treatment status. Neurobiol Dis. 2022 08; 170:105780.
    View in: PubMed
    Score: 0.112
  87. Gut-Brain Communication in Parkinson's Disease: Enteroendocrine Regulation by GLP-1. Curr Neurol Neurosci Rep. 2022 07; 22(7):335-342.
    View in: PubMed
    Score: 0.112
  88. Gender and pramipexole effects on levodopa pharmacokinetics and pharmacodynamics. Neurology. 2002 May 14; 58(9):1418-22.
    View in: PubMed
    Score: 0.112
  89. Placebo-associated improvements in motor function: comparison of subjective and objective sections of the UPDRS in early Parkinson's disease. Mov Disord. 2002 Mar; 17(2):283-8.
    View in: PubMed
    Score: 0.110
  90. Validation of the Arabic Version of the Movement Disorder Society-Unified Parkinson's Disease Rating Scale. Mov Disord. 2022 04; 37(4):826-841.
    View in: PubMed
    Score: 0.110
  91. Rating scales for medication adherence in people living with Parkinson's disease: a systematic review protocol. JBI Evid Synth. 2022 01 01; 20(1):260-269.
    View in: PubMed
    Score: 0.109
  92. Prospective longitudinal assessment of hallucinations in Parkinson's disease. Neurology. 2001 Dec 11; 57(11):2078-82.
    View in: PubMed
    Score: 0.108
  93. Effect of Urate-Elevating Inosine on Early Parkinson Disease Progression: The SURE-PD3 Randomized Clinical Trial. JAMA. 2021 09 14; 326(10):926-939.
    View in: PubMed
    Score: 0.107
  94. Early morning off-medication dyskinesias, dystonia, and choreic subtypes. Arch Neurol. 2001 Sep; 58(9):1379-82.
    View in: PubMed
    Score: 0.106
  95. Prognostic Modeling of Parkinson's Disease Progression Using Early Longitudinal Patterns of Change. Mov Disord. 2021 12; 36(12):2853-2861.
    View in: PubMed
    Score: 0.106
  96. Validation of the Polish version of the Unified Dyskinesia Rating Scale (UDysRS). Neurol Neurochir Pol. 2021; 55(2):186-194.
    View in: PubMed
    Score: 0.102
  97. Genetic variation analysis in parkinson disease patients with and without hallucinations: case-control study. Arch Neurol. 2001 Feb; 58(2):209-13.
    View in: PubMed
    Score: 0.102
  98. In Support of Electronic Versions of Movement Disorder Society Rating Scales. Mov Disord. 2021 01; 36(1):270-271.
    View in: PubMed
    Score: 0.102
  99. COVID-19 Vaccination for Persons with Parkinson's Disease: Light at the End of the Tunnel? J Parkinsons Dis. 2021; 11(1):3-8.
    View in: PubMed
    Score: 0.102
  100. Menstrual-related changes in motoric function in women with Parkinson's disease. Neurology. 2000 Nov 28; 55(10):1572-5.
    View in: PubMed
    Score: 0.101
  101. Acute orthostatic hypotension when starting dopamine agonists in Parkinson's disease. Arch Neurol. 2000 Oct; 57(10):1461-3.
    View in: PubMed
    Score: 0.100
  102. Olanzapine and clozapine: comparative effects on motor function in hallucinating PD patients. Neurology. 2000 Sep 26; 55(6):789-94.
    View in: PubMed
    Score: 0.100
  103. Visual hallucinations induced by deep brain stimulation in Parkinson's disease. Clin Neuropharmacol. 2000 Sep-Oct; 23(5):287-9.
    View in: PubMed
    Score: 0.099
  104. Validation of the Hebrew Version of the Unified Dyskinesia Rating Scale. Neuroepidemiology. 2020; 54(4):356-362.
    View in: PubMed
    Score: 0.098
  105. Item Response Theory Analysis of the MDS-UPDRS Motor Examination: Tremor vs. Nontremor Items. Mov Disord. 2020 09; 35(9):1587-1595.
    View in: PubMed
    Score: 0.097
  106. Differential progression of motor impairment in levodopa-treated Parkinson's disease. Mov Disord. 2000 May; 15(3):479-84.
    View in: PubMed
    Score: 0.097
  107. Impaired frontostriatal cognitive functioning following posteroventral pallidotomy in advanced Parkinson's disease. Brain Cogn. 2000 Apr; 42(3):348-63.
    View in: PubMed
    Score: 0.096
  108. Neuropsychological and behavioral aspects of transplants in Parkinson's disease and Huntington's disease. Brain Cogn. 2000 Mar; 42(2):294-306.
    View in: PubMed
    Score: 0.096
  109. [Visual hallucinations in Parkinson and Charles Bonnet Syndrome patients. A phenomenological and pathogenetic comparison]. Fortschr Neurol Psychiatr. 2000 Mar; 68(3):129-36.
    View in: PubMed
    Score: 0.096
  110. Objective changes in motor function during placebo treatment in PD. Neurology. 2000 Feb 08; 54(3):710-4.
    View in: PubMed
    Score: 0.095
  111. Decreased color discrimination and contrast sensitivity in Parkinson's disease. J Neurol Sci. 2000 Jan 01; 172(1):7-11.
    View in: PubMed
    Score: 0.095
  112. Sex differences by design and outcome in the Safety of Urate Elevation in PD (SURE-PD) trial. Neurology. 2019 10 01; 93(14):e1328-e1338.
    View in: PubMed
    Score: 0.093
  113. Successful use of the Unified Dyskinesia Rating Scale regardless of PD- or dyskinesia-duration. Parkinsonism Relat Disord. 2019 10; 67:113-116.
    View in: PubMed
    Score: 0.093
  114. Parkinson's disease. Clin Neuropharmacol. 1999 Jul-Aug; 22(4):184-91.
    View in: PubMed
    Score: 0.091
  115. Scales to assess impulsive and compulsive behaviors in Parkinson's disease: Critique and recommendations. Mov Disord. 2019 06; 34(6):791-798.
    View in: PubMed
    Score: 0.091
  116. Switching dopamine agonists in advanced Parkinson's disease: is rapid titration preferable to slow? Neurology. 1999 Apr 12; 52(6):1227-9.
    View in: PubMed
    Score: 0.090
  117. Delayed recognition memory in Parkinson's disease: a role for working memory? Neuropsychologia. 1999 Apr; 37(4):503-10.
    View in: PubMed
    Score: 0.090
  118. The Parkinson's disease e-diary: Developing a clinical and research tool for the digital age. Mov Disord. 2019 05; 34(5):676-681.
    View in: PubMed
    Score: 0.090
  119. Hallucinations in Parkinson's disease: the clinical syndrome. Adv Neurol. 1999; 80:419-23.
    View in: PubMed
    Score: 0.088
  120. Rating scales for dyskinesias in Parkinson's disease. Mov Disord. 1999; 14 Suppl 1:48-53.
    View in: PubMed
    Score: 0.088
  121. Early dopaminergic drug-induced hallucinations in parkinsonian patients. Neurology. 1998 Sep; 51(3):811-4.
    View in: PubMed
    Score: 0.086
  122. Validation of the MDS clinical diagnostic criteria for Parkinson's disease. Mov Disord. 2018 10; 33(10):1601-1608.
    View in: PubMed
    Score: 0.086
  123. Movement disorder society criteria for clinically established early Parkinson's disease. Mov Disord. 2018 10; 33(10):1643-1646.
    View in: PubMed
    Score: 0.086
  124. Factor structure of the Unified Parkinson's Disease Rating Scale: Motor Examination section. Mov Disord. 1998 Jul; 13(4):633-6.
    View in: PubMed
    Score: 0.085
  125. Highlights of the North American and European experiences. Neurology. 1998 May; 50(5 Suppl 5):S15-6.
    View in: PubMed
    Score: 0.084
  126. Influence of COMT inhibition on levodopa pharmacology and therapy. Neurology. 1998 May; 50(5 Suppl 5):S26-30.
    View in: PubMed
    Score: 0.084
  127. New lessons from old drugs: amantadine and Parkinson's disease. Neurology. 1998 May; 50(5):1211-2.
    View in: PubMed
    Score: 0.084
  128. Relationship between the MDS-UPDRS and Quality of Life: A large multicenter study of 3206 patients. Parkinsonism Relat Disord. 2018 07; 52:83-89.
    View in: PubMed
    Score: 0.084
  129. Reply: MoCA for cognitive screening in Parkinson's disease: Beware of floor effect. Mov Disord. 2018 03; 33(3):499-500.
    View in: PubMed
    Score: 0.083
  130. Intravenous levodopa in hallucinating Parkinson's disease patients: high-dose challenge does not precipitate hallucinations. Neurology. 1998 Feb; 50(2):515-7.
    View in: PubMed
    Score: 0.083
  131. Global scales for cognitive screening in Parkinson's disease: Critique and recommendations. Mov Disord. 2018 02; 33(2):208-218.
    View in: PubMed
    Score: 0.082
  132. Efficacy of a patient-training videotape on motor fluctuations for on-off diaries in Parkinson's disease. Mov Disord. 1997 Nov; 12(6):1039-41.
    View in: PubMed
    Score: 0.082
  133. Validation of the Hebrew version of the Movement Disorder Society-Unified Parkinson's Disease Rating Scale. Parkinsonism Relat Disord. 2017 Dec; 45:7-12.
    View in: PubMed
    Score: 0.081
  134. Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy. Mov Disord. 2017 Sep; 32(9):1264-1310.
    View in: PubMed
    Score: 0.081
  135. Topiramate as an adjunct to amantadine in the treatment of dyskinesia in parkinson's disease: A randomized, double-blind, placebo-controlled multicenter study. Mov Disord. 2017 09; 32(9):1335-1336.
    View in: PubMed
    Score: 0.080
  136. New strategies with dopaminergic drugs: modified formulations of levodopa and novel agonists. Exp Neurol. 1997 Mar; 144(1):17-20.
    View in: PubMed
    Score: 0.078
  137. Robust graft survival and normalized dopaminergic innervation do not obligate recovery in a Parkinson disease patient. Ann Neurol. 2017 Jan; 81(1):46-57.
    View in: PubMed
    Score: 0.077
  138. Comparison of neuropathology in Parkinson's disease subjects with and without deep brain stimulation. Mov Disord. 2017 02; 32(2):274-277.
    View in: PubMed
    Score: 0.077
  139. Disability Rating Scales in Parkinson's Disease: Critique and Recommendations. Mov Disord. 2016 10; 31(10):1455-1465.
    View in: PubMed
    Score: 0.076
  140. Abolishing the 1-year rule: How much evidence will be enough? Mov Disord. 2016 11; 31(11):1623-1627.
    View in: PubMed
    Score: 0.076
  141. A Phase 2A Trial of the Novel mGluR5-Negative Allosteric Modulator Dipraglurant for Levodopa-Induced Dyskinesia in Parkinson's Disease. Mov Disord. 2016 09; 31(9):1373-80.
    View in: PubMed
    Score: 0.074
  142. There is a renaissance of interest in pallidotomy for Parkinson's disease. Nat Med. 1996 May; 2(5):510-4.
    View in: PubMed
    Score: 0.073
  143. The new definition and diagnostic criteria of Parkinson's disease. Lancet Neurol. 2016 05; 15(6):546-8.
    View in: PubMed
    Score: 0.073
  144. Measurement instruments to assess posture, gait, and balance in Parkinson's disease: Critique and recommendations. Mov Disord. 2016 09; 31(9):1342-55.
    View in: PubMed
    Score: 0.073
  145. Parkinson's disease-related fatigue: A case definition and recommendations for clinical research. Mov Disord. 2016 05; 31(5):625-31.
    View in: PubMed
    Score: 0.072
  146. Gene delivery of neurturin to putamen and substantia nigra in Parkinson disease: A double-blind, randomized, controlled trial. Ann Neurol. 2015 Aug; 78(2):248-57.
    View in: PubMed
    Score: 0.069
  147. Teaching tape for the motor section of the unified Parkinson's disease rating scale. Mov Disord. 1995 May; 10(3):263-6.
    View in: PubMed
    Score: 0.069
  148. Mortality and hallucinations in nursing home patients with advanced Parkinson's disease. Neurology. 1995 Apr; 45(4):669-71.
    View in: PubMed
    Score: 0.068
  149. Diagnosing PD-MCI by MDS Task Force criteria: how many and which neuropsychological tests? Mov Disord. 2015 Mar; 30(3):402-6.
    View in: PubMed
    Score: 0.067
  150. Akathisia in Parkinson's disease. Mov Disord. 1994 Sep; 9(5):545-9.
    View in: PubMed
    Score: 0.065
  151. Utility of an objective dyskinesia rating scale for Parkinson's disease: inter- and intrarater reliability assessment. Mov Disord. 1994 Jul; 9(4):390-4.
    View in: PubMed
    Score: 0.065
  152. The past, present, and future of telemedicine for Parkinson's disease. Mov Disord. 2014 Jun; 29(7):871-83.
    View in: PubMed
    Score: 0.064
  153. Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson's disease. Mov Disord. 2014 Apr; 29(4):454-62.
    View in: PubMed
    Score: 0.063
  154. The role of surgery in Parkinson's disease management. Neurology. 1994 Mar; 44(3 Suppl 1):S17-20.
    View in: PubMed
    Score: 0.063
  155. Physical therapy and Parkinson's disease: a controlled clinical trial. Neurology. 1994 Mar; 44(3 Pt 1):376-8.
    View in: PubMed
    Score: 0.063
  156. Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial. JAMA Neurol. 2014 Feb; 71(2):141-50.
    View in: PubMed
    Score: 0.063
  157. Using cognitive pretesting in scale development for Parkinson's disease: the Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) example. J Parkinsons Dis. 2014; 4(3):395-404.
    View in: PubMed
    Score: 0.063
  158. Fetal-tissue transplantation for Parkinson's disease. N Engl J Med. 1993 Nov 11; 329(20):1498; author reply 1499-500.
    View in: PubMed
    Score: 0.062
  159. Risk factors for nursing home placement in advanced Parkinson's disease. Neurology. 1993 Nov; 43(11):2227-9.
    View in: PubMed
    Score: 0.062
  160. Defining optimal cutoff scores for cognitive impairment using Movement Disorder Society Task Force criteria for mild cognitive impairment in Parkinson's disease. Mov Disord. 2013 Dec; 28(14):1972-9.
    View in: PubMed
    Score: 0.062
  161. Movement disorder society unified Parkinson disease rating scale experiences in daily living: longitudinal changes and correlation with other assessments. Mov Disord. 2013 Dec; 28(14):1980-6.
    View in: PubMed
    Score: 0.062
  162. Measurement of costs and scales for outcome evaluation in health economic studies of Parkinson's disease. Mov Disord. 2014 Feb; 29(2):169-76.
    View in: PubMed
    Score: 0.061
  163. The MDS-UPDRS Part II (motor experiences of daily living) resulted useful for assessment of disability in Parkinson's disease. Parkinsonism Relat Disord. 2013 Oct; 19(10):889-93.
    View in: PubMed
    Score: 0.060
  164. Dissociations among daytime sleepiness, nighttime sleep, and cognitive status in Parkinson's disease. Parkinsonism Relat Disord. 2013 Sep; 19(9):806-11.
    View in: PubMed
    Score: 0.060
  165. Diffusion tensor imaging of Parkinson's disease, atypical parkinsonism, and essential tremor. Mov Disord. 2013 Nov; 28(13):1816-22.
    View in: PubMed
    Score: 0.060
  166. Blood levodopa levels and unified Parkinson's disease rating scale function: with and without exercise. Neurology. 1993 May; 43(5):1040-2.
    View in: PubMed
    Score: 0.060
  167. Force control deficits in individuals with Parkinson's disease, multiple systems atrophy, and progressive supranuclear palsy. PLoS One. 2013; 8(3):e58403.
    View in: PubMed
    Score: 0.059
  168. How to identify tremor dominant and postural instability/gait difficulty groups with the movement disorder society unified Parkinson's disease rating scale: comparison with the unified Parkinson's disease rating scale. Mov Disord. 2013 May; 28(5):668-70.
    View in: PubMed
    Score: 0.059
  169. Which dyskinesia scale best detects treatment response? Mov Disord. 2013 Mar; 28(3):341-6.
    View in: PubMed
    Score: 0.059
  170. [Fetal and adrenal transplantation in Parkinson disease: theoretical bases and clinical results]. Bull Soc Sci Med Grand Duche Luxemb. 1993; 130(1):25-36.
    View in: PubMed
    Score: 0.058
  171. Neurosurgical horizons in Parkinson's disease. Neurology. 1993 Jan; 43(1):1-7.
    View in: PubMed
    Score: 0.058
  172. Ideational fluency in Parkinson's disease. Brain Cogn. 1992 Nov; 20(2):236-44.
    View in: PubMed
    Score: 0.058
  173. Validation of the Italian version of the Movement Disorder Society--Unified Parkinson's Disease Rating Scale. Neurol Sci. 2013 May; 34(5):683-7.
    View in: PubMed
    Score: 0.056
  174. Dopaminergic agonists in the treatment of Parkinson's disease. Neurol Clin. 1992 May; 10(2):527-40.
    View in: PubMed
    Score: 0.056
  175. Entorhinal cortex atrophy differentiates Parkinson's disease patients with and without dementia. Mov Disord. 2012 May; 27(6):727-34.
    View in: PubMed
    Score: 0.055
  176. United Parkinson Foundation Neurotransplantation Registry on adrenal medullary transplants: presurgical, and 1- and 2-year follow-up. Neurology. 1991 Nov; 41(11):1719-22.
    View in: PubMed
    Score: 0.054
  177. Subject-investigator reproducibility of the Unified Parkinson's Disease Rating Scale. Parkinsonism Relat Disord. 2012 Mar; 18(3):230-3.
    View in: PubMed
    Score: 0.054
  178. The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease. Mov Disord. 2011 Oct; 26 Suppl 3:S2-41.
    View in: PubMed
    Score: 0.053
  179. The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson's disease. Mov Disord. 2011 Oct; 26 Suppl 3:S42-80.
    View in: PubMed
    Score: 0.053
  180. Validation of the MDS-UPDRS Part I for nonmotor symptoms in Parkinson's disease. Mov Disord. 2012 Jan; 27(1):79-83.
    View in: PubMed
    Score: 0.053
  181. Health-related quality-of-life scales in Parkinson's disease: critique and recommendations. Mov Disord. 2011 Nov; 26(13):2371-80.
    View in: PubMed
    Score: 0.053
  182. The Movement Disorders task force review of dysautonomia rating scales in Parkinson's disease with regard to symptoms of orthostatic hypotension. Mov Disord. 2011 Sep; 26(11):1985-92.
    View in: PubMed
    Score: 0.052
  183. Priorities in Parkinson's disease research. Nat Rev Drug Discov. 2011 May; 10(5):377-93.
    View in: PubMed
    Score: 0.052
  184. Putative chromaffin cell survival and enhanced host-derived TH-fiber innervation following a functional adrenal medulla autograft for Parkinson's disease. Ann Neurol. 1991 Apr; 29(4):405-12.
    View in: PubMed
    Score: 0.052
  185. Effects of head trauma from motor vehicle accidents on Parkinson's disease. Ann Neurol. 1991 Feb; 29(2):191-3.
    View in: PubMed
    Score: 0.051
  186. Dopaminergic agonists in the treatment of Parkinson's disease. Neurology. 1990 Oct; 40(10 Suppl 3):suppl 50-4; discussion 54-7.
    View in: PubMed
    Score: 0.050
  187. A 12-year population-based study of psychosis in Parkinson disease. Arch Neurol. 2010 Aug; 67(8):996-1001.
    View in: PubMed
    Score: 0.049
  188. Task force report on scales to assess dyskinesia in Parkinson's disease: critique and recommendations. Mov Disord. 2010 Jul 15; 25(9):1131-42.
    View in: PubMed
    Score: 0.049
  189. Shaking up the Salpetriere: Jean-Martin Charcot and mercury-induced tremor. Neurology. 2010 May 25; 74(21):1739-42.
    View in: PubMed
    Score: 0.049
  190. Missing pieces in the Parkinson's disease puzzle. Nat Med. 2010 Jun; 16(6):653-61.
    View in: PubMed
    Score: 0.049
  191. Fatigue rating scales critique and recommendations by the Movement Disorders Society task force on rating scales for Parkinson's disease. Mov Disord. 2010 May 15; 25(7):805-22.
    View in: PubMed
    Score: 0.049
  192. Adrenal medullary transplant to the striatum of patients with advanced Parkinson's disease: 1-year motor and psychomotor data. Neurology. 1990 Feb; 40(2):273-6.
    View in: PubMed
    Score: 0.048
  193. United Parkinson Foundation Neurotransplantation Registry: multicenter US and Canadian data base, presurgical and 12 month follow-up. Prog Brain Res. 1990; 82:611-7.
    View in: PubMed
    Score: 0.047
  194. Scales to evaluate psychosis in Parkinson's disease. Parkinsonism Relat Disord. 2009 Dec; 15 Suppl 3:S38-41.
    View in: PubMed
    Score: 0.047
  195. Development and progression of motor fluctuations and side effects in Parkinson's disease: comparison of Sinemet CR versus carbidopa/levodopa. Neurology. 1989 Nov; 39(11 Suppl 2):63-6; discussion 72-3.
    View in: PubMed
    Score: 0.047
  196. A longitudinal program for biomarker development in Parkinson's disease: a feasibility study. Mov Disord. 2009 Oct 30; 24(14):2081-90.
    View in: PubMed
    Score: 0.047
  197. Using global statistical tests in long-term Parkinson's disease clinical trials. Mov Disord. 2009 Sep 15; 24(12):1732-9.
    View in: PubMed
    Score: 0.046
  198. Agonist substitution in advanced Parkinson's disease. Neurology. 1989 Aug; 39(8):1121-2.
    View in: PubMed
    Score: 0.046
  199. Reducing dosing frequency of carbidopa/levodopa: double-blind crossover study comparing twice-daily bilayer formulation of carbidopa/levodopa (IPX054) versus 4 daily doses of standard carbidopa/levodopa in stable Parkinson disease patients. Clin Neuropharmacol. 2009 Jul-Aug; 32(4):189-92.
    View in: PubMed
    Score: 0.046
  200. Testing objective measures of motor impairment in early Parkinson's disease: Feasibility study of an at-home testing device. Mov Disord. 2009 Mar 15; 24(4):551-6.
    View in: PubMed
    Score: 0.045
  201. [Where are the grafts in Parkinson's disease?]. Rev Prat. 1989 Mar 09; 39(8):675-7.
    View in: PubMed
    Score: 0.045
  202. Clinical pattern and risk factors for dyskinesias following fetal nigral transplantation in Parkinson's disease: a double blind video-based analysis. Mov Disord. 2009 Feb 15; 24(3):336-43.
    View in: PubMed
    Score: 0.045
  203. Multicenter study of autologous adrenal medullary transplantation to the corpus striatum in patients with advanced Parkinson's disease. N Engl J Med. 1989 Feb 09; 320(6):337-41.
    View in: PubMed
    Score: 0.045
  204. The Unified Dyskinesia Rating Scale: presentation and clinimetric profile. Mov Disord. 2008 Dec 15; 23(16):2398-403.
    View in: PubMed
    Score: 0.044
  205. Risk factors for progression in Parkinson's disease. Neurology. 1988 Dec; 38(12):1841-4.
    View in: PubMed
    Score: 0.044
  206. Controlled-release carbidopa/levodopa (CR4-Sinemet) in Parkinson's disease patients with and without motor fluctuations. Neurology. 1988 Jul; 38(7):1143-6.
    View in: PubMed
    Score: 0.043
  207. Serum urate as a predictor of clinical and radiographic progression in Parkinson disease. Arch Neurol. 2008 Jun; 65(6):716-23.
    View in: PubMed
    Score: 0.042
  208. Case 2, 1988. Congenital mental retardation and juvenile parkinsonism. Mov Disord. 1988; 3(4):352-61.
    View in: PubMed
    Score: 0.041
  209. Diagnostic procedures for Parkinson's disease dementia: recommendations from the movement disorder society task force. Mov Disord. 2007 Dec; 22(16):2314-24.
    View in: PubMed
    Score: 0.041
  210. Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord. 2007 Sep 15; 22(12):1689-707; quiz 1837.
    View in: PubMed
    Score: 0.040
  211. Controlled-release Sinemet. Neurology. 1987 Sep; 37(9):1567-8.
    View in: PubMed
    Score: 0.040
  212. Levodopa-induced dyskinesias. Mov Disord. 2007 Jul 30; 22(10):1379-1389.
    View in: PubMed
    Score: 0.040
  213. Parkinson's disease and motor fluctuations: long-acting carbidopa/levodopa (CR-4-Sinemet). Neurology. 1987 May; 37(5):875-8.
    View in: PubMed
    Score: 0.039
  214. The etiopathogenesis of Parkinson disease and suggestions for future research. Part II. J Neuropathol Exp Neurol. 2007 May; 66(5):329-36.
    View in: PubMed
    Score: 0.039
  215. The etiopathogenesis of Parkinson disease and suggestions for future research. Part I. J Neuropathol Exp Neurol. 2007 Apr; 66(4):251-7.
    View in: PubMed
    Score: 0.039
  216. Progression of Parkinson's disease without levodopa. Neurology. 1987 Apr; 37(4):695-8.
    View in: PubMed
    Score: 0.039
  217. DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology. 2007 Mar 13; 68(11):812-9.
    View in: PubMed
    Score: 0.039
  218. Apolipoprotein E gene polymorphism, total plasma cholesterol level, and Parkinson disease dementia. Arch Neurol. 2007 Feb; 64(2):261-5.
    View in: PubMed
    Score: 0.039
  219. Relationships among pain, depression, and sleep alterations in Parkinson's disease. Adv Neurol. 1987; 45:345-7.
    View in: PubMed
    Score: 0.038
  220. Open-label flexible-dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease. Mov Disord. 2006 Dec; 21(12):2078-81.
    View in: PubMed
    Score: 0.038
  221. Rasagiline-associated motor improvement in PD occurs without worsening of cognitive and behavioral symptoms. J Neurol Sci. 2006 Oct 25; 248(1-2):78-83.
    View in: PubMed
    Score: 0.037
  222. A randomized controlled trial of etilevodopa in patients with Parkinson disease who have motor fluctuations. Arch Neurol. 2006 Feb; 63(2):210-6.
    View in: PubMed
    Score: 0.036
  223. Hallucinations in Parkinson disease in the prelevodopa era. Neurology. 2006 Jan 10; 66(1):93-8.
    View in: PubMed
    Score: 0.036
  224. Charcot on Parkinson's disease. Mov Disord. 1986; 1(1):27-32.
    View in: PubMed
    Score: 0.036
  225. Pain in Parkinson's disease. Mov Disord. 1986; 1(1):45-9.
    View in: PubMed
    Score: 0.036
  226. Autonomic dysfunction in Parkinson's disease. Neurology. 1986 Jan; 36(1):73-5.
    View in: PubMed
    Score: 0.036
  227. Chronic agonist therapy for Parkinson's disease: a 5-year study of bromocriptine and pergolide. Neurology. 1985 May; 35(5):749-51.
    View in: PubMed
    Score: 0.034
  228. Repeated visual hallucinations in Parkinson's disease as disturbed external/internal perceptions: focused review and a new integrative model. Mov Disord. 2005 Feb; 20(2):130-40.
    View in: PubMed
    Score: 0.034
  229. A responsive outcome for Parkinson's disease neuroprotection futility studies. Ann Neurol. 2005 Feb; 57(2):197-203.
    View in: PubMed
    Score: 0.034
  230. Non-linearity of Parkinson's disease progression: implications for sample size calculations in clinical trials. Clin Trials. 2005; 2(6):509-18.
    View in: PubMed
    Score: 0.034
  231. Altered cortical visual processing in PD with hallucinations: an fMRI study. Neurology. 2004 Oct 26; 63(8):1409-16.
    View in: PubMed
    Score: 0.033
  232. Genetic polymorphisms in Parkinson disease subjects with and without hallucinations: an analysis of the cholecystokinin system. Arch Neurol. 2004 Aug; 61(8):1280-4.
    View in: PubMed
    Score: 0.033
  233. Bupropion in Parkinson's disease. Neurology. 1984 Aug; 34(8):1092-4.
    View in: PubMed
    Score: 0.033
  234. Apolipoprotein E controls the risk and age at onset of Parkinson disease. Neurology. 2004 Jun 08; 62(11):2005-9.
    View in: PubMed
    Score: 0.032
  235. Multicenter, open-label, trial of sarizotan in Parkinson disease patients with levodopa-induced dyskinesias (the SPLENDID Study). Clin Neuropharmacol. 2004 Mar-Apr; 27(2):58-62.
    View in: PubMed
    Score: 0.032
  236. Pergolide in Parkinson's disease. Arch Neurol. 1983 Dec; 40(13):785-7.
    View in: PubMed
    Score: 0.031
  237. Glutathione S-transferase omega-1 modifies age-at-onset of Alzheimer disease and Parkinson disease. Hum Mol Genet. 2003 Dec 15; 12(24):3259-67.
    View in: PubMed
    Score: 0.031
  238. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann Neurol. 2003 Sep; 54(3):403-14.
    View in: PubMed
    Score: 0.031
  239. Association study of Parkin gene polymorphisms with idiopathic Parkinson disease. Arch Neurol. 2003 Jul; 60(7):975-80.
    View in: PubMed
    Score: 0.030
  240. Longitudinal outcome of Parkinson's disease patients with psychosis. Neurology. 2003 Jun 10; 60(11):1756-61.
    View in: PubMed
    Score: 0.030
  241. Parkin mutations and susceptibility alleles in late-onset Parkinson's disease. Ann Neurol. 2003 May; 53(5):624-9.
    View in: PubMed
    Score: 0.030
  242. Genetic polymorphisms of the N-acetyltransferase genes and risk of Parkinson's disease. Neurology. 2003 Apr 08; 60(7):1189-91.
    View in: PubMed
    Score: 0.030
  243. Mitochondrial polymorphisms significantly reduce the risk of Parkinson disease. Am J Hum Genet. 2003 Apr; 72(4):804-11.
    View in: PubMed
    Score: 0.029
  244. A 6-month trial of pergolide mesylate in the treatment of idiopathic Parkinson's disease. Adv Neurol. 1983; 37:75-83.
    View in: PubMed
    Score: 0.029
  245. Drug holiday in the management of Parkinson disease. Clin Neuropharmacol. 1982 Dec; 5(4):351-64.
    View in: PubMed
    Score: 0.029
  246. A pure parkinsonian syndrome following acute carbon monoxide intoxication. Arch Neurol. 1982 May; 39(5):302-4.
    View in: PubMed
    Score: 0.028
  247. Pharmacology of hallucinations induced by long-term drug therapy. Am J Psychiatry. 1982 Apr; 139(4):494-7.
    View in: PubMed
    Score: 0.028
  248. Age at onset in two common neurodegenerative diseases is genetically controlled. Am J Hum Genet. 2002 Apr; 70(4):985-93.
    View in: PubMed
    Score: 0.028
  249. Complete genomic screen in Parkinson disease: evidence for multiple genes. JAMA. 2001 Nov 14; 286(18):2239-44.
    View in: PubMed
    Score: 0.027
  250. Association of single-nucleotide polymorphisms of the tau gene with late-onset Parkinson disease. JAMA. 2001 Nov 14; 286(18):2245-50.
    View in: PubMed
    Score: 0.027
  251. Weekly drug holiday in Parkinson disease. Neurology. 1981 Nov; 31(11):1460-2.
    View in: PubMed
    Score: 0.027
  252. CPK values in Parkinson's disease. N Engl J Med. 1981 Jun 25; 304(26):1608-9.
    View in: PubMed
    Score: 0.026
  253. Practical guidelines for drug holidays in parkinsonian patients. Neurology. 1981 May; 31(5):641-2.
    View in: PubMed
    Score: 0.026
  254. Induction by dopamine D1 receptor agonist ABT-431 of dyskinesia similar to levodopa in patients with Parkinson disease. Arch Neurol. 2001 Feb; 58(2):249-54.
    View in: PubMed
    Score: 0.026
  255. Application of the Unified Parkinson's Disease Rating Scale in progressive supranuclear palsy: factor analysis of the motor scale. Mov Disord. 2000 Mar; 15(2):276-9.
    View in: PubMed
    Score: 0.024
  256. "On" freezing in Parkinson's disease: resistance to visual cue walking devices. Mov Disord. 2000 Mar; 15(2):309-12.
    View in: PubMed
    Score: 0.024
  257. Effects of central dopaminergic stimulation by apomorphine on speech in Parkinson's disease. Neurology. 2000 Jan 25; 54(2):458-62.
    View in: PubMed
    Score: 0.024
  258. Levodopa in the treatment of Parkinson's disease: a consensus meeting. Mov Disord. 1999 Nov; 14(6):911-3.
    View in: PubMed
    Score: 0.023
  259. The first miracle in neurodegenerative disease: the discovery of oral levodopa. Brain Res Bull. 1999 Nov-Dec; 50(5-6):377-8.
    View in: PubMed
    Score: 0.023
  260. Use of placebo surgery in controlled trials of a cellular-based therapy for Parkinson's disease. N Engl J Med. 1999 Sep 23; 341(13):988-92.
    View in: PubMed
    Score: 0.023
  261. Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson's disease. Ann Neurol. 1999 Sep; 46(3):419-24.
    View in: PubMed
    Score: 0.023
  262. The alpha-synuclein gene is not a major risk factor in familial Parkinson disease. Neurogenetics. 1999 Sep; 2(3):191-2.
    View in: PubMed
    Score: 0.023
  263. Factor analysis of the motor section of the unified Parkinson's disease rating scale during the off-state. Mov Disord. 1999 Jul; 14(4):585-9.
    View in: PubMed
    Score: 0.023
  264. Hallucinations, sleep fragmentation, and altered dream phenomena in Parkinson's disease. Mov Disord. 1999 Jan; 14(1):117-21.
    View in: PubMed
    Score: 0.022
  265. Poor visual discrimination and visual hallucinations in Parkinson's disease. Clin Neuropharmacol. 1998 Sep-Oct; 21(5):289-95.
    View in: PubMed
    Score: 0.022
  266. Clinical presentation and pharmacological therapy in corticobasal degeneration. Arch Neurol. 1998 Jul; 55(7):957-61.
    View in: PubMed
    Score: 0.021
  267. Accuracy of the clinical diagnoses of Lewy body disease, Parkinson disease, and dementia with Lewy bodies: a clinicopathologic study. Arch Neurol. 1998 Jul; 55(7):969-78.
    View in: PubMed
    Score: 0.021
  268. Metric properties of nurses' ratings of parkinsonian signs with a modified Unified Parkinson's Disease Rating Scale. Neurology. 1997 Dec; 49(6):1580-7.
    View in: PubMed
    Score: 0.021
  269. Effect of stereotaxic intrastriatal cografts of autologous adrenal medulla and peripheral nerve in Parkinson's disease: two-year follow-up study. Exp Neurol. 1997 Oct; 147(2):510-7.
    View in: PubMed
    Score: 0.020
  270. The stability of carbidopa in solution. Mov Disord. 1997 Jul; 12(4):608-10.
    View in: PubMed
    Score: 0.020
  271. Treatment with fetal allografts. Neurology. 1997 Jun; 48(6):1737-8.
    View in: PubMed
    Score: 0.020
  272. Dopaminergic transplants in patients with Parkinson's disease: neuroanatomical correlates of clinical recovery. Exp Neurol. 1997 Mar; 144(1):41-6.
    View in: PubMed
    Score: 0.019
  273. Alpha-tocopherol in the ventricular cerebrospinal fluid of Parkinson's disease patients: dose-response study and correlations with plasma levels. Neurology. 1996 Oct; 47(4):1037-42.
    View in: PubMed
    Score: 0.019
  274. Genetic variability of the CYP 2D6 gene is not a risk factor for sporadic Parkinson's disease. Ann Neurol. 1996 Sep; 40(3):463-5.
    View in: PubMed
    Score: 0.019
  275. Case 1, 1996: rapidly progressive parkinsonism, incontinence, impotency, and levodopa-induced moaning in a patient with multiple myeloma. Mov Disord. 1996 May; 11(3):298-310.
    View in: PubMed
    Score: 0.018
  276. Prevalence of parkinsonian signs and associated mortality in a community population of older people. N Engl J Med. 1996 Jan 11; 334(2):71-6.
    View in: PubMed
    Score: 0.018
  277. Levodopa stability in solution: time course, environmental effects, and practical recommendations for clinical use. Mov Disord. 1996 Jan; 11(1):24-6.
    View in: PubMed
    Score: 0.018
  278. MDS clinical diagnostic criteria for Parkinson's disease. Mov Disord. 2015 Oct; 30(12):1591-601.
    View in: PubMed
    Score: 0.018
  279. MDS research criteria for prodromal Parkinson's disease. Mov Disord. 2015 Oct; 30(12):1600-11.
    View in: PubMed
    Score: 0.018
  280. Pramipexole in patients with early Parkinson's disease. Clin Neuropharmacol. 1995 Aug; 18(4):338-47.
    View in: PubMed
    Score: 0.017
  281. Factors predictive of the need for levodopa therapy in early, untreated Parkinson's disease. The Parkinson Study Group. Arch Neurol. 1995 Jun; 52(6):565-70.
    View in: PubMed
    Score: 0.017
  282. A practical approach to remote longitudinal follow-up of Parkinson's disease: the FOUND study. Mov Disord. 2014 May; 29(6):743-9.
    View in: PubMed
    Score: 0.016
  283. Double-blind, placebo-controlled, crossover study of duodenal infusion of levodopa/carbidopa in Parkinson's disease patients with 'on-off' fluctuations. Neurology. 1993 Sep; 43(9):1698-703.
    View in: PubMed
    Score: 0.015
  284. Striatal extracts from patients with Parkinson's disease promote dopamine neuron growth in mesencephalic cultures. Exp Neurol. 1993 Mar; 120(1):149-52.
    View in: PubMed
    Score: 0.015
  285. Blinded evaluation confirms long-term asymmetric effect of unilateral thalamotomy or subthalamotomy on tremor in Parkinson's disease. Neurology. 1992 Jul; 42(7):1311-4.
    View in: PubMed
    Score: 0.014
  286. Core assessment program for intracerebral transplantations (CAPIT). Mov Disord. 1992; 7(1):2-13.
    View in: PubMed
    Score: 0.014
  287. Effect of MK-458 (HPMC) in Parkinson's disease previously untreated with dopaminergic drugs. A double-blind, placebo-controlled multicenter study. Clin Neuropharmacol. 1991 Aug; 14(4):322-9.
    View in: PubMed
    Score: 0.013
  288. The potential use of a dopamine neuron antibody and a striatal-derived neurotrophic factor as diagnostic markers in Parkinson's disease. Neurology. 1991 May; 41(5 Suppl 2):53-8; discussion 59-60.
    View in: PubMed
    Score: 0.013
  289. Clinical improvement in parkinsonian patients undergoing adrenal to caudate transplantation is not reflected by chromogranin A or basic fibroblast growth factor in ventricular fluid. Exp Neurol. 1991 Mar; 111(3):276-81.
    View in: PubMed
    Score: 0.013
  290. Autologous transplantation of adrenal medulla in Parkinson's disease. 18-month results. Arch Neurol. 1990 Dec; 47(12):1286-9.
    View in: PubMed
    Score: 0.013
  291. Variable expression of Parkinson's disease: a base-line analysis of the DATATOP cohort. The Parkinson Study Group. Neurology. 1990 Oct; 40(10):1529-34.
    View in: PubMed
    Score: 0.012
  292. Disappearance of a putative DA-neuron antibody following adrenal medulla transplantation: relationship to a striatal-derived DA neuron trophic factor. Prog Brain Res. 1990; 82:693-7.
    View in: PubMed
    Score: 0.012
  293. Evaluation of a modified inverted walking stick as a treatment for parkinsonian freezing episodes. Mov Disord. 1990; 5(3):243-7.
    View in: PubMed
    Score: 0.012
  294. Hypersexuality with antiparkinsonian therapy. Clin Neuropharmacol. 1989 Oct; 12(5):375-83.
    View in: PubMed
    Score: 0.012
  295. Environmental factors and Parkinson's disease: a case-control study in China. Neurology. 1989 May; 39(5):660-4.
    View in: PubMed
    Score: 0.011
  296. An antibody in the CSF of Parkinson's disease patients disappears following adrenal medulla transplantation. Neurosci Lett. 1988 Nov 22; 94(1-2):192-7.
    View in: PubMed
    Score: 0.011
  297. The adrenal medullary transplant operation for Parkinson's disease: clinical observations in five patients. Neurosurgery. 1988 Jun; 22(6 Pt 1):999-1004.
    View in: PubMed
    Score: 0.011
  298. Hemiparkinsonism with hemiatrophy. Neurology. 1988 Apr; 38(4):527-30.
    View in: PubMed
    Score: 0.010
  299. Amantadine and motor fluctuations in chronic Parkinson's disease. Clin Neuropharmacol. 1987 Dec; 10(6):522-6.
    View in: PubMed
    Score: 0.010
  300. Pergolide mesylate: four years experience in Parkinson's disease. Adv Neurol. 1987; 45:547-9.
    View in: PubMed
    Score: 0.010
  301. Drug-induced myoclonus. Adv Neurol. 1986; 43:251-64.
    View in: PubMed
    Score: 0.009
  302. Pergolide mesylate: lack of cardiac toxicity in patients with cardiac disease. Neurology. 1985 Jun; 35(6):918-21.
    View in: PubMed
    Score: 0.009
  303. Levodopa-free periods ("drug holidays") in the management of parkinsonism. Adv Neurol. 1983; 37:33-43.
    View in: PubMed
    Score: 0.007
  304. Pergolide mesylate and idiopathic Parkinson disease. Neurology. 1982 Oct; 32(10):1175-9.
    View in: PubMed
    Score: 0.007
  305. Drug-induced extrapyramidal disorders - a neuropsychiatric interface. J Clin Psychopharmacol. 1981 Sep; 1(5):297-303.
    View in: PubMed
    Score: 0.007
  306. The effect of bromocriptine (BCT) on the on-off phenomenon. J Neural Transm. 1981; 52(1-2):41-7.
    View in: PubMed
    Score: 0.006
  307. Chronic agonist-induced hypersensitivity and on-off hyperkinesis. Ann Neurol. 1979 Sep; 6(3):277-8.
    View in: PubMed
    Score: 0.006
  308. Lergotrile in the treatment of parkinsonism. Neurology. 1978 Jul; 28(7):699-702.
    View in: PubMed
    Score: 0.005
  309. Recent advances in the biochemical pharmacology of extrapyramidal movement disorders. Adv Exp Med Biol. 1977; 90:21-47.
    View in: PubMed
    Score: 0.005
  310. Drug-induced asterixis in Parkinson disease. Neurology. 1982 May; 32(5):553-5.
    View in: PubMed
    Score: 0.002
  311. Complications of chronic levodopa therapy: long-term efficacy of drug holiday. Neurology. 1981 Apr; 31(4):473-6.
    View in: PubMed
    Score: 0.002
  312. Levodopa-induced myoclonus. Arch Neurol. 1975 May; 32(5):330-4.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.